ArticleCNS drugs2018

Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Dimitrios Papadopoulos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.